tbuckley/cabot-search huggingface dataset:
Dropout from Brief Psychotherapy in Anorexia nervosa
Authors: S. Fassino, G. Abbate Daga, A. Pierò, G.G. Rovera
Journal: Psychotherapy and Psychosomatics (2002)

Dropout from psychotherapy is an important issue that has received little systematic attention. This study investigated the phenomenon of dropout from brief psychotherapy for anorexia nervosa (AN).99 outpatients suffering from AN of the restrictor type (n = 53) or binge/purging type (n = 46) were evaluated. Their clinical and personal characteristics were recorded, and body mass index was calculated for participants. They were administered the Eating Disorder Inventory-II (EDI-II), the State-Trait Anger Expression Inventory (STAXI) and the Temperament and Character Inventory (TCI).Significant differences in some baseline psychopathologic (EDI-II, STAXI) and personality (TCI) variables emerged from the comparison between dropouts and completers. Patients who dropped out of the treatment showed higher levels of anger temperament, anger expression-in and expression-out and lower scores for the dimensions of character (low self-directedness and low cooperativeness). No differences were found between the two groups regarding sociodemographic and clinical variables.Dropout from brief psychotherapy seems to be related to either psychopathologic or personality aspects, such as the tendency to repress anger, which is encountered also in psychosomatic disorders, and the presence of more compromised dimensions of character, typical of subjects with personality disorders. This study of dropout from brief psychotherapy in AN provided interesting results that will need further confirmation. Possible implications for treatment are addressed.
Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications
Authors: Xin Yao, Chao-Nan Qian, Zhong-Fa Zhang, Min-Han Tan, Eric J. Kort, Ximing J. Yang, James H. Resau, Bin Tean Teh
Journal: Clinical Cancer Research (2007)

Abstract Purpose: Intratumoral microvascular density (MVD) has been controversial as an indicator of prognosis in clear cell renal cell carcinoma (CCRCC). Classification of the intratumoral blood vessels based on differential expressions of blood vessel markers has not been correlated with patient prognosis in CCRCC. In this study, we aimed to evaluate the association of different categories of blood vessels with the patients' outcomes. Experimental Design: Seventy-eight CCRCC patients who underwent nephrectomy alone were enrolled. Paraffin-embedded CCRCC tissues, together with 16 nonmalignant kidney cortex tissues, were used in tissue microarray analyses and conventional section analyses. The characteristics of intratumoral blood vessels were identified by multiple blood vessel markers and pericyte markers. A computerized image analysis program was used to quantitatively calculate the vascular density. Results: Two distinct types of microvessels were identified in CCRCC: undifferentiated (CD31+/CD34−) and differentiated (CD34+) vessels. A higher undifferentiated MVD significantly correlated with higher tumor grades and shorter patient survival. In contrast, a higher differentiated MVD significantly correlated with lower tumor grade and longer survival. Multivariate analyses showed that undifferentiated MVD was an independent prognostic factor for patient survival. An inverse correlation between undifferentiated MVD and differentiated MVD was also identified in CCRCC. Conclusions: This is the first report showing distinct types of vasculature in CCRCC correlated with contrasting prognoses. A refined classification of CCRCC based on vasculature is therefore important for evaluating prognosis, and it may also have therapeutic implications.
Abstract 1445: The metastasis suppressor NM23-H1 promotes genomic stability through its 3’-5’ exonuclease and nucleoside diphosphate kinase activities following UV irradiation
Authors: Stuart G. Jarrett, Marian Novak, Nathan Harris, Isabel Mellon, Andrezj Slominski, Sandrine Arnaud-Dabernat, Jean-Yves Daniel, David M. Kaetzel
Journal: Cancer Research (2011)

Abstract NM23-H1 is a metastasis suppressor whose reduced expression is associated with aggressive forms of melanoma, hepatoma, and carcinomas of the breast, stomach and colon. The current study has identified NM23-H1 (termed H1 isoform in human, M1 in mouse) and two of its attendant enzymatic activities, the 3’-5’ exonuclease and nucleoside diphosphate kinase (NDPK), as novel participants in the response to UV-induced DNA damage. Kinetics of repair for total DNA polymerase-blocking lesions and nucleotide excision pathway-mediated repair of 6-4 photoproducts were significantly compromised in different cellular settings of NM23-H1-deficiency. These included the human melanoma cell line WM793 and embryo fibroblasts (MEFs) derived from mouse strains rendered deficient in either NM23-M1 alone or both the M1 and M2 isoforms in tandem. The NDPK activity of NM23-H1 was critical for early repair of both polychromatic UVB/UVA (275-400 nm)- and UVC (254 nm)-induced DNA damage. Elevated rates of spontaneous and UV-induced mutations were observed in WM793 cells and NM23-deficient MEFs. The mutational spectra reflected aberrant repair of 6-4 photoproducts and oxidatively-induced DNA damage, with the 3’-5’ exonuclease being the principal enzymatic activity required to reduce UV-induced mutagenesis. This study has provided the first evidence for an essential role of mammalian NM23 isoforms in maintaining genomic stability. This novel anti-mutator function appears relevant not only to the metastasis suppressor activity of NM23-H1, but also possibly resistance to UV-induced carcinogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1445. doi:10.1158/1538-7445.AM2011-1445
Circadian Variations in the Occurrence of Cardiac Arrests
Authors: Monika Peckova, Carol E. Fahrenbruch, Leonard A. Cobb, Alfred P. Hallstrom
Journal: Circulation (1998)

Background —Patterns of temporal variation of cardiac arrests may be important for understanding mechanisms leading to the onset of acute cardiovascular disorders. Previous studies reported diurnal variation of the onset of cardiac arrests, with high incidence in the morning and in the evening, lack of daily variation during the week, and some seasonal variation. The association between the time of day and recurrent cardiac arrests has not been previously examined. Methods and Results —We explored temporal variation in 6603 out-of-hospital cardiac arrests attended by the Seattle Fire Department. The data exhibit diurnal variation, with a low incidence at night and two peaks of approximately the same size (at 8 to 11 am and 4 to 7 pm ). The evening peak is attributed primarily to the patients found in ventricular fibrillation, whereas arrests that show other rhythms exhibit mainly a morning peak. Cardiac arrests associated with survival have more pronounced diurnal variation than episodes in which survival did not occur. This difference persists after adjustment for rhythm. For 597 patients who had at least two separate cardiac arrests, we found no overall association between the times of day of the recurrent arrests. For women, however, the times of day of the first and second arrests were closer to each other than one would expect if the times were entirely unrelated. Conclusions —Cardiac arrests do not occur randomly during the day, but rather follow certain periodic patterns. These patterns are probably associated with patterns of daily activities. The hypothesis that cardiac arrests are triggered by a person’s activity rather than by some underlying characteristics of his or her disease is supported by the lack of association between the times of the first and second arrests in the patients with recurrent arrests.
Abstract ES09-1: Update on management of ER positive metastatic breast cancer
Authors: HJ Burstein
Journal: Cancer Research (2013)

Abstract Patients with ER positive, metastatic breast cancer are candidate for endocrine and chemotherapy treatments in order to prolong survival, alleviate and forestall symptoms, and preserve quality of life. Classical management strategies such as the prompt initiation of ovarian suppression at the time of diagnosis of metastatic disease, the sequential use of treatment with endocrine agents and chemotherapeutic agents, the predilection of ER positive tumors for bone / soft tissue / mucosal and lymph nodes as initial sites of metastatic disease, and the lack of close correlation between clinical benefit and overt treatment response to endocrine agents remain valuable observations. Despite decades of clinical use, important new findings regarding endocrine therapy continue to emerge. Several examples of recent innovation include the following. 1. Dosing of fulvestrant. Because of limited bioavailability in its injectable formulation, higher doses of fulvestrant (500 mg) yield superior clinical outcomes than seen with the lower doses (250 mg) originally used for drug approval. 2. Combinations of aromatase inhibitors and fulvestrant. Historically, single-agent endocrine treatment has been the norm. Recent studies have examined AI therapy given with or without fulvestrant. In the FACT trial, no substantial benefit was observed. However, in the SWOG 0221 study, the combination led to improved overall survival, perhaps because this patient population had received less in the way of prior endocrine treatment. 3. Novel pathways: mTOR inhibitors. Everolimus, the orally available mTOR inhibitor, is now FDA approved for use in AI-refractory breast cancer based on the BOLERO-2 study which showed that adding everolimus improved PFS compared to ongoing AI therapy, alone. To date, genomic biomarkers have not lent themselves to clinical use for patient selection of mTOR inhibitor therapy. 4. Novel pathways: CDK4/6 inhibitors. Novel agents are targeting the CDK4/6 pathway in ER+ metastatic breast cancer, and show early promise in randomized phase II studies. 5. Use of estrogens as treatment for advanced breast cancer. Harkening back to observations from the 1950s and 1960s, investigators have shown in small phase II trials that estrogen therapy itself can achieve tumor regression and clinical benefit in ER+ metastatic breast cancer. 6. Genomic revolution. Full genome sequencing is now available for many ER+ advanced cancers, identifying frequent mtuations in many genes (PIK3CA, FGFR, IGFR, AKT, CCND1 and other genes that may lend themselves to targeted therapeutic approaches. In addition to these innovations in targeted the ER and related pathways, it is also becoming clear chemotherapy outcomes for women with ER+ breast cancer are effective, and often more effective than in the treatment of TNBC which is more often considered a “chemotherapy-treated” tumor. These advances and other insights into ER positive metastatic breast cancer will be discussed. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr ES09-1.
Induction of the epidermal growth factor receptor and its ligands in nasal epithelium by ozone
Authors: Riccardo Polosa, Raymond J Sapsford, Dejan Dokic, Rossella R Cacciola, Gaetano Prosperini, Jagdish L Devalia, Stephen T Holgate, Peter H Howarth, Donna E Davies
Journal: Journal of Allergy and Clinical Immunology (2004)
Disorders of the Knee
Authors: Kingsbury G. HEIPLE
Journal: JAMA (1974)

<b>Diseases of the Knee Joint</b>, by I. S. Smillie, 459 pp, with illus, $55, Churchill Livingstone (Longman Inc, 72 5th Ave, NY 10011), 1974. Both of these authors are well known to the orthopedic community for outstanding books on internal derangements of the knee. Their previous volumes have been largely restricted to acute and subacute traumatic disorders of the knee and as such have been of somewhat limited scope. The present volumes represent an effort to approach a more adequate coverage of the broad spectrum of knee-joint disease and surgery rather than that strictly limited to trauma and internal derangement. Dr. Helfet takes his previous work on the management of internal derangements of the knee, and by adding a series of chapters by guest authors, expands it into broader coverage of knee-joint disorders. This has been of only limited success. The individual contributions on biomechanics of the knee, structure and
Abstract P4-15-02: Timing of infectious complications following breast conserving therapy with catheter-based accelerated partial breast irradiation
Authors: AB Haynes, ES Bloom, I Bedrosian, HM Kuerer, RF Hwang, AS Caudle, KK Hunt, L Graviss, RF Chemaly, W Tereffe, SF Shaitelman, GV Babiera
Journal: Cancer Research (2012)

Abstract Background: Accelerated partial breast irradiation (APBI) has been introduced as an alternative to whole breast irradiation as part of breast conserving therapy for selected patients. The long-term outcomes remain under investigation. Previous publications have emphasized early postoperative infections with APBI with less focus on delayed infection. In the current study, we evaluated patients enrolled on a prospective registry trial for infectious complications after treatment with catheter-based APBI. Methods: Patients who underwent single-entry catheter-based APBI were identified from a single-institution prospective registry from 2009 to 2011. Data regarding treatment, patient comorbidities, complications, and outcomes were obtained from registry and retrospective chart review. Infectious complications were assessed from the date of APBI catheter insertion and were classified as early (≤30 days) or delayed (&amp;gt;30 days). All patients were maintained on oral antibiotics while the catheter was in place. Results: A total of 91 patients with 92 cases of primary breast cancer were enrolled on a prospective registry at a comprehensive cancer center between 2009 and 2011 and treated with single-entry catheter-based APBI. The median follow-up time was 76.2 weeks. A temporary catheter was placed at the time of initial operation in 40 cases (43.5%) and left in place a median of 6 days prior to definitive catheter insertion. There were 20 patients (21.7%) who required re-excision. Overall, breast infection occurred in 13 (14.1%) patients. Three (3.3%) patients had infection within 30 days of catheter placement and 10 (10.9%) occurred more than 30 days after catheter insertion (median 112.5 days, interquartile range 51–154). Eight patients were managed with oral antibiotics alone on an outpatient basis. The remainder required a combination of admission, intravenous antibiotics, and aspiration of abscess. One patient underwent operative drainage. Conclusion: We found an overall infection rate of 14.1% in patients treated with catheter-based APBI. This is consistent with other reports; however, we found that the majority of infections occurred more than 30 days after definitive catheter placement. Vigilance for infectious complications must continue beyond the immediate treatment period in patients undergoing catheter-based APBI. Most infections following APBI can be managed on an outpatient basis without operative intervention. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-15-02.
Amsacrine is safe in patients with ventricular ectopy
Authors: Carmelo A. Puccio, Eric J. Feldman, Zalmen A. Arlin
Journal: American Journal of Hematology (1988)

Abstract Amsacrine is an active antileukemic agent known to induce cardiac arrhythmias, although the incidence of these cardiac events is low. Rhythm abnormalities associated with amsacrine use include the development of fatal tachyarrhythmias, but this risk can be minimized by ensuring a normal serum potassium level prior to drug administration. Even though amsacrine has been given safely to patients with pre‐existing supraventricular arrhythmias, its safety in patients with ventricular ectopy has not been addressed. We describe two patients who underwent treatment with amsacrine without developing life‐threatening dysrhythmias and show that ventricular ectopy does not contraindicate therapy with this agent.
279 PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS
Authors: K.A. Byrnes-Blake, J.A. Freeman, M.G. Dodds, L. Rapalus, S. Pederson, N. Hunder, D.M. Miller
Journal: Journal of Hepatology (2010)
965 SENSITIVITY AND SPECIFICITY OF ALPHA-FETO PROTEIN (AFP), LENS CULINARIS AGGLUTININ-REACTIVE AFP (AFP-L3) AND DES- GAMMA-CARBOXYPROTHROMBIN (DCP) AS TUMOR MARKERS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
Authors: J.M. Ertle, M. Wiehert, R. Küper, P. Hilgard, G. Gerken, J. Schlaak
Journal: Journal of Hepatology (2011)
Reduced seroconversion to measles in infants given vitamin A with measles vaccination
Authors: Z. Munasir, A. Akib, J. Beeler, S. Audet, None Muhilal, R.D. Semba, A. Sommer
Journal: The Lancet (1995)

Administration of 100000 IU vitamin A at the time of measles immunisation is currently recommended for infants in developing countries. However, the safety and value of giving vitamin A, a potent immune enhancer, with live measles virus vaccines are unknown. We conducted a randomised, double-blind, placebo-controlled clinical trial in Indonesia to evaluate the effect of simultaneous vitamin A supplementation on the immune response to measles immunisation at six months of age. 336 infants received either vitamin A (100000 IU) or placebo when immunised with standard-titre Schwarz measles vaccine. 82% of infants seroconverted to measles. In a multiple logistic regression model adjusting for maternal antibody titres, vitamin A supplementation was associated with a lower likelihood of seroconversion to measles (odds ratio 0.40, 95% Cl 0.19-0.88), and girls were less likely to seroconvert than boys (0.34, 0.15-0.76). Immunisation with standard-titre Schwarz vaccine at six months of age in this study population is characterised by high seroconversion rates. However, simultaneous high-dose vitamin A may interfere with seroconversion to live measles vaccine in infants with maternal antibody.
Performance and injury incidence rate in home and away games in Iran Premier League teams
Authors: Mostafa Zarei, Nader Rahnama, Effat Bambaeichi
Journal: British Journal of Sports Medicine (2010)

In soccer, home advantage is a very important factor in determining the outcome of a game. The main purpose of this study was to compare the performance and injury incidence rate in home and away games in Iran Premier League. The information about the number of wins and losses, received and scored goals, yellow and red cards in home and away teams were obtained via the website of http://www.iplstats.com. Then, videotapes for 253 matches of this league were selected and analysed. The results showed that when teams played at home, they scored significantly higher points than when they played away (t = 4.2, p&lt;0.05). The number of wins in home games was significantly higher than in the away games (t = 3.8, p&lt;0.05). The number of losses in away games was higher than home games (t =−4.6, p&lt;0.05). Injury rate for away teams was significantly higher than for home teams (Z = 1.98, p&lt;0.05) (57.6 injuries per 1000 h vs 72.01 injuries per 1000 h). Consequently, the results showed more ideal performance of the teams in home games. The rate of injury in away teams was significantly higher than in home teams. Thus, these factors must be considered by team coaches and physicians to prevent injuries and enhance performance.
Corrigendum to: ''Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators'' [Cardiovascular Research 36 (1997) 246–255]
Authors: S Daggubati
Journal: Cardiovascular Research (1999)

Fig. 1 of the article by Daggubati et al. in Cardiovascular Research 1997;36:246-255 was inadvertently the plotted values for high performance gel permeation chromatography (HP-GPC) of healthy individuals rather than the plotted values of patients with congestive heart failure as shown overleaf.



Fig. 1 
High-performance gel permeation chromatography evidence that (A) atrial natriuretic peptide prohormone (proANP) 1–30, (B) atrial natriuretic peptide prohormone (proANP) 31–67, (C) atrial natriuretic peptide (ANP), and (D) …
Managing osteoarthritis of the knee
Authors: Florence Tubach, P Ravaud, B Giraudeau
Journal: BMJ (2005)

Developing primary palliative care Continuity of care is paramount but needs to be tailored individuallyEditor-Riley suggests that completion of a form detailing palliative care management should be mandatory for general practitioners. 1 I have spent a great deal of time promoting palliative medicine in primary care, with variable success.Much depends on the individual practitioner's experience and interest, which probably accounts for the variable success of handover forms to communicate with out of hours services.Making this a compulsory part of general practice might bring all practice to the same level.But the initial answer to the question, "Would I be surprised if my patient died in the next 12 months?"would then make the difference.Cynical practitioners would probably answer no for nearly all of their patients, for the longer you practise the less often you are surprised.But, in truth, for many patients in general practice the answer to this question would be no: many elderly patients who live in nursing or residential homes, nearly all patients with chronic disease, including heart disease, chronic obstructive pulmonary disease, neurological disease, and so on.The workload in handing these patients over to the out of hours service would be huge, more so for the out of hours service than the individual practice.Continuity of care for patients who most need it is paramount, including all those with chronic disease.However, more sophisticated systems are needed to meet patient needs: perhaps different systems for different diseases, possibly different systems for each stage of a disease.Whatever the system, it must meet the needs of the individual patient.This entails dialogue between primary care (including out of hours), secondary care, and tertiary care to thrash out the detail.
Catecholamine Uptake, Accumulation, and Release in Acute Porphyria
Authors: M. Flint Beal, Nuzhet O. Atuk, Thomas C. Westfall, Suzanne M. Turner
Journal: Journal of Clinical Investigation (1977)

Hypertension and tachycardia are well known features of acute porphyria and have been shown to be related to increased circulating catecholamines. The mechanism by which circulating catecholamines are increased was studied using the isolated perfused rat heart and human platelets as a model of adrenergic neuronal function. It was found that neither δ-aminolevulinate (ALA) nor porphobilinogen (PBG) blocked uptake or caused release in the isolated perfused rat heart. Platelets from six patients with acute prophyria, three in remission and three latent, with matching normal controls were studied with regard to their uptake of [3H]norepinephrine in the presence of ALA or PBG. It was found that ALA and PBG significantly reduced uptake and accumulation of [3H]-norepinephrine in patients with acute porphyria; however, no similar reduction in uptake and accumulation was observed in the platelets of normal controls. Therefore, it appears that there is a latent defect in the catecholamine uptake and (or) accumulation of platelets of patients with acute prophyria which only manifests itself in the presence of ALA or PBG. If platelet uptake serves as a model of adrenergic neuron uptake, this suggests that elevated circulating catecholamine levels during acute attacks of acute porphyria are caused at least partially by blockade of re-uptake into the sympathetic neurons.